Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Targeting SS18-SSX biology in synovial sarcomagenesis
FY 2021-22
Summary
Drug-Targeting Drivers of Synovial Sarcoma DevelopmentSynovial sarcoma is an aggressive soft-tissue cancer primarily affecting adolescents and young adults and has a 5-year survival rate of ~15% with disseminated disease. Synovial sarcoma is caused by a specific mutationfusion of the SS18 gene to the SSX geneproducing a new protein, SS18-SSX. Understanding the effects of SS18-SSX is key to uncovering the underlying pathogenesis of synovial sarcoma and developing better therapies.We created a novel mouse model to study synovial sarcoma, which closely recapitulates the disease seen in humans, by genetically engineering mouse connective tissue stem cells to produce SS18-SSX. All mutant mice develop synovial sarcoma at ~16 weeks of age, demonstrating reproducibility and the strong effects of this mutation. As we can detect and analyze mouse cells throughout the course of tumor development, this model can reveal vulnerabilities based on the signals this cancer relies on to form, grow and spread.Our model and previous literature have identified Wnt signaling as one key pathway activated by SS18-SSX. Wnt signaling allows cells to proliferate, invade surrounding tissue, and metastasize by disrupting the bonds that normally connect cells to other cells. Thus, we will investigate how using drugs to block Wnt signaling affects the ability of SS18-SSX to drive cancer progression.We will treat mice with drugs currently approved for clinical trials to inhibit Wnt and look for changes in tumor growth, invasiveness, metastatic spread and mouse survival. With these investigations, we can evaluate the feasibility of treating synovial sarcoma with drug-inhibitors of Wnt, gain a better understanding of cancer development, and inform the development of new and effective therapies.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
466506
Name
Wang Xue Q
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeting SS18-SSX biology in synovial sarcomagenesis
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Drug Testing; In Vivo; Mice Models; Synovial Sarcoma
Abstract
Drug-Targeting Drivers of Synovial Sarcoma DevelopmentSynovial sarcoma is an aggressive soft-tissue cancer primarily affecting adolescents and young adults and has a 5-year survival rate of ~15% with disseminated disease. Synovial sarcoma is caused by a specific mutationfusion of the SS18 gene to the SSX geneproducing a new protein, SS18-SSX. Understanding the effects of SS18-SSX is key to uncovering the underlying pathogenesis of synovial sarcoma and developing better therapies.We created a novel mouse model to study synovial sarcoma, which closely recapitulates the disease seen in humans, by genetically engineering mouse connective tissue stem cells to produce SS18-SSX. All mutant mice develop synovial sarcoma at ~16 weeks of age, demonstrating reproducibility and the strong effects of this mutation. As we can detect and analyze mouse cells throughout the course of tumor development, this model can reveal vulnerabilities based on the signals this cancer relies on to form, grow and spread.Our model and previous literature have identified Wnt signaling as one key pathway activated by SS18-SSX. Wnt signaling allows cells to proliferate, invade surrounding tissue, and metastasize by disrupting the bonds that normally connect cells to other cells. Thus, we will investigate how using drugs to block Wnt signaling affects the ability of SS18-SSX to drive cancer progression.We will treat mice with drugs currently approved for clinical trials to inhibit Wnt and look for changes in tumor growth, invasiveness, metastatic spread and mouse survival. With these investigations, we can evaluate the feasibility of treating synovial sarcoma with drug-inhibitors of Wnt, gain a better understanding of cancer development, and inform the development of new and effective therapies.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wang, Xue Q
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~